These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38008773)

  • 1. Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy.
    Shi S; Zhou M; Wang G; Xu J; Zhang D; Zheng M; Zhang S
    Cancer Control; 2023; 30():10732748231214936. PubMed ID: 38008773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic and predictive value of mismatch repair status in patients with locally advanced rectal cancer following neoadjuvant therapy.
    Wu Z; Hu H; Wang C; Zhang J; Cai Y; Xie X; Huang Y; Deng Y
    Ann Transl Med; 2022 Apr; 10(8):491. PubMed ID: 35571401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mismatch repair system deficiency is associated with chemoradiotherapy resistance in locally advanced rectal adenocarcinoma patients.
    Ni K; Zhan Y; Liu Z; Zhao XZ; Wang W; Wang G; Zhang Z; Li G; Zhang X; Zhang C
    J Surg Oncol; 2022 Mar; 125(4):692-702. PubMed ID: 34918842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of rectal cancer patients after neoadjuvant chemoradiotherapy: different prognostic factors in patients with different TRGs.
    Tang YL; Li DD; Duan JY; Wang X
    Int J Colorectal Dis; 2024 Jun; 39(1):93. PubMed ID: 38896374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone.
    Ni K; Zhan Y; Liu Z; Yuan Z; Wang S; Zhao XZ; Ping H; Liu Y; Wang W; Yan S; Xin R; Han Q; Zhang Q; Li G; Zhang X; Wang G; Zhang Z; Ma H; Zhang C
    BMC Cancer; 2023 Oct; 23(1):1013. PubMed ID: 37864137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy.
    Pretta A; Ziranu P; Giampieri R; Pinna G; Randon G; Donisi C; Ravarino A; Loi F; Deias G; Palmas E; Pretta G; Morano F; Semonella F; Mariani S; Deidda MA; Pusceddu V; Puzzoni M; Lai E; Solinas C; Restivo A; Zorcolo L; Barbara R; Berardi R; Faa G; Pietrantonio F; Scartozzi M
    Br J Cancer; 2023 Nov; 129(10):1619-1624. PubMed ID: 37749283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes of different neoadjuvant treatment regimens in patients with locally advanced rectal cancer and MRI-detected extramural venous invasion.
    Chen M; Ma Y; Song YW; Huang J; Gao YH; Zheng J; He F
    Cancer Med; 2023 Nov; 12(21):20523-20537. PubMed ID: 37864414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy.
    Dou X; Wang R; Meng X; Yan H; Jiang S; Zhu K; Xu X; Chen D; Song X; Mu D
    Cancer Biomark; 2015; 15(2):181-8. PubMed ID: 25519018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients.
    Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS
    PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy.
    Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J
    J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.
    de Rosa N; Rodriguez-Bigas MA; Chang GJ; Veerapong J; Borras E; Krishnan S; Bednarski B; Messick CA; Skibber JM; Feig BW; Lynch PM; Vilar E; You YN
    J Clin Oncol; 2016 Sep; 34(25):3039-46. PubMed ID: 27432916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Impact of the Neoadjuvant Rectal Score as Compared With the Tumor Regression Grade and Yield Pathologic TNM Stage in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy.
    Baek JH; Baek DW; Kang BW; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
    In Vivo; 2020; 34(4):1993-1999. PubMed ID: 32606172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mismatch Repair-Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy.
    Cercek A; Dos Santos Fernandes G; Roxburgh CS; Ganesh K; Ng S; Sanchez-Vega F; Yaeger R; Segal NH; Reidy-Lagunes DL; Varghese AM; Markowitz A; Wu C; Szeglin B; Sauvé CG; Salo-Mullen E; Tran C; Patel Z; Krishnan A; Tkachuk K; Nash GM; Guillem J; Paty PB; Shia J; Schultz N; Garcia-Aguilar J; Diaz LA; Goodman K; Saltz LB; Weiser MR; Smith JJ; Stadler ZK
    Clin Cancer Res; 2020 Jul; 26(13):3271-3279. PubMed ID: 32144135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer.
    Zhu K; Zhao Q; Yue J; Shi P; Yan H; Xu X; Wang R
    Oncotarget; 2016 Oct; 7(42):68328-68338. PubMed ID: 27634904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study.
    Zhao L; Fu Y; Niu P; Zhang F; Jiao F; Zhou X; Wu Z; Wang W; Luan X; Han X; He M; Guan Q; Li Y; Zhao D; Gao J; Chen Y
    Oncologist; 2023 Oct; 28(10):e891-e901. PubMed ID: 37104872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and predictive value of mismatch repair deficiency in gastric and gastroesophageal junction adenocarcinoma patients receiving neoadjuvant or adjuvant chemotherapy.
    Li Z; Wang Y; Ying X; Zhang L; Gao X; Jia Y; Zhang L; Wu A; Su X; Ji J
    J Surg Oncol; 2021 Dec; 124(8):1356-1364. PubMed ID: 34515995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.